Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of British Columbia

$29,500.00

Antibody venom conjugates

EF 2021-22

Résumé
Antibody Drug Conjugates (ADCs) are an emerging class of drugs that combines antibody and drug payload. The antibody targets the drug payload to specific targeted cells improving both safety and efficacy. To date that are 8 FDA approved ADC drugs all for oncology application using small molecule drugs. Although these ADCs with small molecules encompasses superior efficacy and safety than non-targeted small molecule drugs, it is increasingly evident that they succumb to the same multi-drug resistance by the cancer cells. In this project, we are exploring the synthesis and evaluation of larger molecule cyclical peptide toxin drugs that cancer cells will not be able to develop resistance to. This proposal merges unique chemical training outcomes in the Perrin lab on bioconjugation of novel venom-derived peptides to antibodies with an industrial partnership with iProgen, an emerging biopharmaceutical company in Vancouver. With a short time-frame, we have identified a qualified postdoctoral fellow who has experience in peptides and is prepared to engage in this project.Traditionally, these cyclic peptide toxins are rarely used for oncology application due to a variety of systemic toxicity; however, by utilizing an ADC platform, we hypothesize that this new class of toxins may represent an important and untapped class of anti-cancer drug payloads to be unlocked. The Perrin lab has extensive experience in the synthesis and evaluation of cyclic and bicyclic peptides including the synthesis of both phalloidins and amanitins, which showcase know-how in this domain and as toxins represent back-up molecules as we advance new toxic scaffolds as payloads for ADCs. Outcomes will be first-in-class compositions of chemically conjugated toxins to antibodies that will be validated in vitro by our industrial partner, iProgen.
Programme
Alliance Grants
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
571337-2021
Name nom
Perrin, David
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
29500
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Installment
inst:1
Partie
1
Nb partie
1
Application title
Antibody venom conjugates
Keyword
NSERC
Application summary
Antibody Drug Conjugates (ADCs) are an emerging class of drugs that combines antibody and drug payload. The antibody targets the drug payload to specific targeted cells improving both safety and efficacy. To date that are 8 FDA approved ADC drugs all for oncology application using small molecule drugs. Although these ADCs with small molecules encompasses superior efficacy and safety than non-targeted small molecule drugs, it is increasingly evident that they succumb to the same multi-drug resistance by the cancer cells. In this project, we are exploring the synthesis and evaluation of larger molecule cyclical peptide toxin drugs that cancer cells will not be able to develop resistance to. This proposal merges unique chemical training outcomes in the Perrin lab on bioconjugation of novel venom-derived peptides to antibodies with an industrial partnership with iProgen, an emerging biopharmaceutical company in Vancouver. With a short time-frame, we have identified a qualified postdoctoral fellow who has experience in peptides and is prepared to engage in this project.Traditionally, these cyclic peptide toxins are rarely used for oncology application due to a variety of systemic toxicity; however, by utilizing an ADC platform, we hypothesize that this new class of toxins may represent an important and untapped class of anti-cancer drug payloads to be unlocked. The Perrin lab has extensive experience in the synthesis and evaluation of cyclic and bicyclic peptides including the synthesis of both phalloidins and amanitins, which showcase know-how in this domain and as toxins represent back-up molecules as we advance new toxic scaffolds as payloads for ADCs. Outcomes will be first-in-class compositions of chemically conjugated toxins to antibodies that will be validated in vitro by our industrial partner, iProgen.